DYRAMID

*Urinary-tract infections:* ORAL: Adult: 200-400 mg daily in themorning; increased if necessary to 400 mg twice daily, in upper urinary tract infections. *Complicated urinary-tract infection:* BY IV INF: Adult: 200 mg daily, increased if necessary to 400 mg twice daily for severe or complicated infections, to be given over at least 30 minutes for each 200 mg. *Acute or chronic prostatitis:* ORAL: Adult: 200 mg twice daily for 28 days. *Lower respiratory-tract infections:* ORAL: Adult: 400 mg daily in themorning, then increased if necessary to 400 mg twice daily. BY IV INF: Adult: 200 mg twice daily, increased to 400 mg twice daily, for severe or complicated infections, to be given over at least 30 minutes for each 200 mg. *Skin and soft-tissue infections:* ORAL: Adult: 400 mg twice daily. BY IV INF: Adult: 400 mg twice daily, to be given over at least 30 minutes for each 200 mg. *Uncomplicated gonorrhea:* ORAL: Adult: 400 mg as a single dose. *Uncomplicated genital chlamydial infection, Nongonococcal urethritis:* ORAL: Adult: 400 mg daily for 7 days, as asingle daily dose or in divided doses. *Pelvic inflammatory disease:* ORAL: Adult: 400 mg twice daily for 14 days. *Septicaemia:* BY IV INF: Adult: 200 mg twice daily, increased if necessary to 400 mg twice daily, for severe or complicated infections, to be given over at least 30 minutes for each 200mg. *Uncomplicated Cystitis:* ORAL: Adult: 200 mg every 12 hr for 3 days (E. coli or K. pneumoniae) or for 7 days (other pathogens), Prostatitis (E. coli): 300 mg every 12 hr for 6 weeks. Children: Not recommended.

Administer over at least 60 min. Infuse separately. Do not infuse though lines containing solutions with magnesium or calcium.

Epilepsy or lowered seizure threshold, history of tendinitis, adolescents,

Ensure adequate fluid intake (risk of crystalluria). Risk factor for QTinterval prolongation; caution advised in conditions such as: Acute myocardial infarction, bradycardia, congenital long QT syndrome, electrolyte disturbances, heart failure with reduced left ventricular ejection fraction, history of symptomatic arrhythmias, history of tendon disorder, epilepsy, history to CNS disorder, renal impairment, myasthenia gravis and elderly. Avoid prolonged exposure to UV. Discontinue treatmentif psychiatric, neurological, or hypersensitivity reactions (including severe rash) occur.

Magnesium or aluminium antacids, sucralfate, glibenclamide and other hypoglycaemics, iron, zinc probenecid, cimetidine, furosemide methotrexate, NSAIDs, anticoagulants, corticosteroids, drugs that prolong the QT Interval. Injection: Barbiturate anaesthetics, hypotensives.

Cough, eye irritation, nasopharyngitis, diarrhoea, dizziness, headache, nausea, vomiting, abdominal pain, anorexia, anxiety, arthralgia, asthenia, blood disorders, confusion, depression, disturbances in vision, dyspepsia, eosinophilia, hallucinations, leucopenia, myalgia, rash, sleep disturbances, thrombocytopenia, tremor. Rare: antibiotic-associated colitis, convulsions, dyspnea, hepatic dysfunction, hepatitis, hypotension, interstitial nephritis, jaundice, photosensitivity, psychoses, renal failure, symptoms of peripheral neuropathy, tendon damage and inflammation, vasculitis